Novo Nordisk Receives FDA Approval of Ozempic (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes

December 5, 2017 -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for Ozempic (semaglutide) injection 0.5 mg or 1 mg, a once-weekly glucagon-like peptide (GLP-1) receptor...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news

Related Links:

The t-SNARE protein SNAP23 conventionally functions as a component of the cellular machinery required for intracellular transport vesicle fusion with target membranes and has been implicated in the regulation of fasting glucose levels, BMI, and type 2 diabetes. Surprisingly, we observed that adipocyte-specific KO of SNAP23 in mice resulted in a temporal development of severe generalized lipodystrophy associated with adipose tissue inflammation, insulin resistance, hyperglycemia, liver steatosis, and early death. This resulted from adipocyte cell death associated with an inhibition of macroautophagy and lysosomal degradatio...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
ConclusionsIn patients with T2D and persistent microalbuminuria, u-KIM-1, but not u-NGAL, was an independent risk factor for decline in eGFR, CVE and all-cause mortality, and contributed significant discrimination for all-cause mortality, beyond traditional risk factors.
Source: Acta Diabetologica - Category: Endocrinology Source Type: research
This report discusses the results of cardiovascular and renal outcomes from the two landmark trials.
Source: Diabetology International - Category: Endocrinology Source Type: research
gorta The prevalence of the so-called diseases of affluence, such as type 2 diabetes or hypertension, has increased dramatically in the last two generations. Although genome-wide association studies (GWAS) have discovered hundreds of genes involved in disease etiology, the sudden increase in disease incidence suggests a major role for environmental risk factors. Obesity constitutes a case example of a modern trait shaped by contemporary environment, although with considerable debates about the extent to which gene-by-environment (G×E) interactions accentuate obesity risk in individuals following obesogenic li...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Article Source Type: research
Called Revita, the device is already used for type 2 diabetes because the burning process, ablation, burns off cells which have become resistant to insulin.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
ConclusionsOur data suggest that glucokinase in brain and other non β-cell peripheral hypoglycemia sensors is important in glucose homeostasis, allowing the body to detect and respond to a falling blood glucose.Graphical abstract
Source: Molecular Metabolism - Category: Endocrinology Source Type: research
GI Dynamics has won a nod from FDA to begin a pivotal trial of the embattled EndoBarrier, a technology used to treat patients with type 2 diabetes. The pivotal trial could be a significant turning point in the life of the Lexington, MA-based company, which was founded in 2004. The firm has been approved for staged enrollment with initial approval for treatment of up to 67 study participants including 50 EndoBarrier and about 17 control participants. GI Dynamics said it expects to complete enrollment of Stage I of the study during the first half of 2019. “This IDE approval is the result of more than two ye...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Implants Source Type: news
Condition:   Type2 Diabetes Interventions:   Drug: CKD-501 0.5mg;   Drug: Placebo Sponsor:   Chong Kun Dang Pharmaceutical Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
GI Dynamics (ASX:GID) said today it won FDA investigational device exemption approval to launch a pivotal trial of its EndoBarrier device designed for treating patients with type 2 diabetes and obesity, pending Institutional Review Board approval. The EndoBarrier device is a plastic gut sleeve designed to prevent the absorption of nutrients from food as it exits the stomach and enters the intestinal tract to treat type 2 diabetes and obesity, the Lexington, Mass.-based company said. The approval is a boon for the company, which has faced a number of hurdles with its device over the past few years, inclu...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Diabetes Food & Drug Administration (FDA) Regulatory/Compliance Weight loss GI Dynamics Source Type: news
MONDAY, Aug. 13, 2018 -- Bariatric surgery is tied to lower overall incidence of microvascular disease in patients with type 2 diabetes mellitus (T2DM), according to a study published online Aug. 7 in the Annals of Internal Medicine. Rebecca...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Food and Drug Administration (FDA) | New Drug Applications